Stallergenes Greer

Stallergenes Greer is a global biopharmaceutical company specializing in the diagnosis and treatment of respiratory allergies through the development and commercialization of allergy immunotherapy products and services. Our purpose is to enable people with allergies to live normal lives. With more than 1,400 employees worldwide, a presence in 22 countries, and manufacturing facilities in both Europe and the United States, Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France). With complementary strengths, joint heritage and reputations, Stallergenes Greer is driving a continuing leadership in allergy immunotherapy.
Type
Public
HQ
London, GB
Founded
2015
Size (employees)
1,395 (est)
Stallergenes Greer was founded in 2015 and is headquartered in London, GB

Stallergenes Greer Office Locations

Stallergenes Greer has an office in London
London, GB (HQ)
40 Bernard St

Stallergenes Greer Metrics

Stallergenes Greer Financial Metrics

Revenue (2015)

£63.5 m

Gross profit

£34.1 m

Gross profit margin (2015), %

54%

Market capitalization (28-Apr-2017)

€677.5 m

Closing share price (28-Apr-2017)

€34.6
Stallergenes Greer's current market capitalization is €677.5 m.
Stallergenes Greer's revenue was reported to be £63.5 m in FY, 2015
FY, 2015

Revenue

£63.5 m

Cost of goods sold

£29.5 m

Gross profit

£34.1 m

Gross profit Margin, %

54%

Operating expense total

£91.4 m

Stallergenes Greer Market Value History

Stallergenes Greer Online Presence

Stallergenes Greer Company Life

You may also be interested in